ESLA
Estrella Immunopharma, Inc.NASDAQHealthcare$1.05+29.52%ClosedMarket Cap: $44.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-4.98
P/S
0.00
EV/EBITDA
-4.34
DCF Value
$0.02
FCF Yield
-3.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
185.8%
ROA
-411.2%
ROIC
126.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-613.2K | $-613.2K | $-0.02 | — |
| FY 2025 | $0.00 | NaN% | $-13.1M | $-13.1M | $-0.35 | — |
| Q3 2025 | $0.00 | NaN% | $-4.8M | $-4.8M | $-0.13 | — |
| Q2 2025 | $0.00 | NaN% | $-5.5M | $-5.5M | $-0.15 | — |
| Q1 2025 | $0.00 | NaN% | $-2.1M | $-2.1M | $-0.06 | — |
| Q4 2024 | $0.00 | NaN% | $-1.1M | $-1.1M | $-0.03 | — |
| FY 2024 | $0.00 | NaN% | $-8.8M | $-8.8M | $-0.25 | — |
| Q3 2024 | $0.00 | NaN% | $-3.4M | $-3.4M | $-0.09 | — |
| Q2 2024 | $0.00 | NaN% | $-3.9M | $-4.0M | $-0.11 | — |
| FY 2023 | $0.00 | NaN% | $-7.3M | $-7.3M | $-0.21 | — |
| Q1 2024 | $0.00 | NaN% | $-469.5K | $-469.5K | $-0.01 | — |
| Q4 2023 | $0.00 | NaN% | $-1.0M | $-1.0M | $-0.03 | — |